What is the Role of Cannabidiol in Refractory Epilepsy

Document Type

Peer-Reviewed Article

Publication Date

2019

Abstract

The FDA recently approved the first cannabidiol oral medication to treat refractory epilepsy in patients with Dravet syndrome and Lennox-Gastaut syndrome. This article describes the safety and efficacy of cannabidiol treatment in patients with refractory epilepsy.

Comments

At the time this article was written, Kathryn M. LaFleur was a student in the Physician Assistant program at Sacred Heart University.

DOI

10.1097/01.JAA.0000553393.36249.df

PMID

30817475

Publication

Journal of the American Academy of PAs

Volume

32

Issue

3

Publisher

Wolters Kluwer

Pages

16-18

Link to Full Text


Share

COinS